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Pharmacokinetics, hemodynamic and metabolic
effects of epinephrine to prevent post-operative
low cardiac output syndrome in children
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Philippe Pouard4 and Jean-Marc Tréluyer2
Abstract
Introduction: The response to exogenous epinephrine (Ep) is difficult to predict given the multitude of factors
involved such as broad pharmacokinetic and pharmacodynamic between-subject variabilities, which may be more
pronounced in children. We investigated the pharmacokinetics and pharmacodynamics of Ep, co-administered with
milrinone, in children who underwent open heart surgical repair for congenital defects following cardiopulmonary
bypass, including associated variability factors.
Methods: Thirty-nine children with a high risk of low cardiac output syndrome were prospectively enrolled. Ep
pharmacokinetics, hemodynamic and metabolic effects were analyzed using the non-linear mixed effects modeling
software MONOLIX. According to the final model, an Ep dosing simulation was suggested.
Results: Ep dosing infusions ranged from 0.01 to 0.23 μg.kg-1.min-1 in children whose weight ranged from 2.5 to
58 kg. A one-compartment open model with linear elimination adequately described the Ep concentration-time
courses. Bodyweight (BW) was the main covariate influencing clearance (CL) and endogenous Ep production rate
(q0) via an allometric relationship: CL(BWi) = θCL x (BWi)
3/4 and q0(BWi) = θq0 x (BWi )
3/4. The increase in heart rate
(HR) and mean arterial pressure (MAP) as a function of Ep concentration were well described using an Emax model.
The effect of age was significant on HR and MAP basal level parameters. Assuming that Ep stimulated the production
rate of plasma glucose, the increases in plasma glucose and lactate levels were well described by turnover models
without any significant effect of age, BW or exogenous glucose supply.
Conclusions: According to this population analysis, the developmental effects of BW and age explained a part of the
pharmacokinetic and pharmacodynamics between-subject variabilities of Ep administration in critically ill children. This
approach ultimately leads to a valuable Ep dosing simulation which should help clinicians to determine an appropriate
a priori dosing regimen.
Introduction
Inotropic agents are commonly administered to prevent
postoperative low cardiac output syndrome (LCOS) fol-
lowing cardiopulmonary bypass (CPB) in children under-
going open heart surgical repair [1]. According to the
PRIMACORP study, milrinone is the first-choice drug [2].
However as described in the European survey EuLoCOS-
Paed, preventive drug therapy is highly variable. For in-
stance, epinephrine (Ep), which is cheaper than other
commonly used catecholamines, is also used, although
evidenced-based data are currently lacking [3,4].
The amplitude of the hemodynamic response to Ep is
difficult to predict given the multitude of factors involved
and clinical experience suggests broad between-subject
variability. This hemodynamic response is primarily
dependent on Ep concentrations. However Ep pharma-
cokinetics has been poorly evaluated in children. Fisher
et al. suggested linear pharmacokinetics with a lower
clearance than that reported in healthy adults, although
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only six children were included in their study and neither
inter-patient variability nor pharmacodynamic effects were
described [5]. A recent adult study using population
pharmacokinetic modeling highlighted the influence of
bodyweight (BW) and disease severity on Ep clearance
confirming this variability [6]. These between-subject
disparities may be even more pronounced in children.
Pediatric dosages of Ep are usually extrapolated from
adult studies. However, postnatal development of cardiac
contractility is associated with major changes in the
modulatory effect of β-adrenoreceptor signaling. More-
over, differential maturation of the transduction pathways
within the cardiomyocyte contributes to age-dependent
changes in cardiac responsiveness and sensitivity to ago-
nists [7]. Although much is known regarding the adult
physiological and pharmacological effects of Ep, there are
very few pediatric studies on Ep pharmacodynamics. Ef-
fects of Ep infusion in children have only been described
in the neonate, mostly in low birth-weight infants, where
effects on heart rate (HR), mean arterial pressure (MAP),
plasma glucose and lactate levels were observed [8].
The purpose of the present study was to investigate,
using a population approach, the pharmacokinetics and
pharmacodynamics of Ep including hemodynamic (HR,
MAP) and metabolic effects (plasma glucose and lactate
levels) in critically ill children undergoing surgical repair
for congenital heart defect, following CPB, as well as as-
sociated variability factors [9]. The effects of develop-
mental and other factors on Ep pharmacokinetics and
pharmacodynamics were investigated in order to better
explain the observed between-subject variabilities and to
ultimately suggest individualized dosage regimens.
Materials and methods
Setting
This prospective study was conducted in a 14-bed surgical
pediatric cardiovascular intensive care unit (pCVICU) of a
tertiary teaching hospital Necker Enfants Malades, Paris
in France from July 2011 to December 2011. The Ethics
committee of the Necker Enfants Malades Hospital ap-
proved the study provided that written and appropriate
consent was obtained from the child’s parent(s) after they
were informed of the objectives. We confirm that we have
all necessary and appropriate consent from each child’s
parents involved in the study, including consent to partici-
pate in the study and consent to publish.
All consecutive children aged less than 18 years, weigh-
ing more than 1,200 g, and requiring Ep infusion following
CPB for open heart surgery were included. Non-inclusion
criteria were unknown initial time infusion of Ep, un-
known time of Ep flow-rate changes or unknown time of
blood sampling. Children were enrolled prior to the onset
of infusion and for a period lasting 6 hours after the start
of Ep administration.
Intervention
In the operating room, all children underwent endo-
tracheal intubation and were mechanically ventilated
under sedation, opioid treatment (midazolam and sufen-
tanil) and neuromuscular blocking agent. Standard mon-
itoring was used, comprising a radial or femoral artery
catheter for measurement of systemic arterial blood
pressure and intermittent blood sampling, a triple-lumen
right internal jugular or femoral central venous catheter
(CVC), and urinary bladder or rectal temperature probes.
Normothermic CPB with intermittent warm blood cardio-
plegia was performed in every patient during the study
period, except in cases where deep hypothermic circula-
tory arrest was indicated. Conventional ultrafiltration was
performed during the CPB.
Ep infusion was initiated in the operating room (defined
as time = 0 minutes), in association with milrinone at the
end of the CPB, according to the local protocol and the
risk of developing an LCOS: risk adjustment for congeni-
tal heart surgery 1 (RACHS-1) category, aortic cross-
clamping duration, preoperative left ventricle dilatation,
preoperative or intraoperative arterial pulmonary hyper-
tension defined by intra cardiac right to left shunt or pul-
monary arterial pressure over 2/3 mean systemic arterial
pressure, hemodynamic instabilities (defined by a variation
greater than 20% of HR and/or MAP) and physiological
status [2,10]. Cases involving sepsis or preoperative myo-
cardial dysfunction requiring inotropic support were
excluded.
Ep (adrenalin 1 mg⋅mL-1, RenaudinTM diluted to
100 μg⋅mL-1 or 50 μg⋅mL-1 in Glucose 5% BaxterTM, UK)
was infused using a programmable electric syringe pump
(DPS, Fresenius VialTM, Brezins, France) through a triple-
lumen central venous catheter (Arrow, TeleflexTM, PA
19605, USA) with a flow rate varying from 0.3 mL⋅h-1
to 1 mL⋅h-1. The latter was adjusted for age and
hemodynamic objectives, namely: normal HR, normal
MAP, normal time capillary refill, normal pulse, nor-
mal urine output (>2 mL⋅kg-1⋅h-1), ScVO2 >70% when
measured, normal transthoracic echocardiography of
left ventricular ejection fraction (60 to 80%) and nor-
mal plasma lactate level (<2.2 mmol⋅L-1) [2,11]. De-
pending on the congenital heart defects and the repair,
the preload was normalized based on CVP and/or left atrial
pressure (LAP). After normalized preload, intravenous mil-
rinone at a dose ranging from 0.3 to 0.5 μg⋅kg-1⋅min-1 was
systematically combined with Ep infusion without loading
bolus at initiation.
Upon arrival to the ICU, medications were adjusted by
the bedside nurse under the direction of the medical
team: blood transfusion to reach a hemoglobin level
above 10 g⋅dL-1, furosemide to maintain water balance
and urine output over 2 mL⋅kg-1⋅h-1. Adequate analgesia
and sedation were ensured by, respectively, continuous
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intravenous morphine or sufentanil and midazolam,
mechanical ventilation with adequate pressure levels
and oxygen inspired fraction and inhaled nitric oxide
in case of pulmonary arterial hypertension.
The daily amount of intravenous glucose was adjusted
for age: birth to 12 months: 4 g⋅kg-1⋅day-1, 12 months to
48 months: 3 g⋅kg-1⋅day-1, 48 months to 72 months:
2.5 g⋅kg-1⋅day-1 and over 72 months: 2 g⋅kg-1⋅day-1.
LCOS was defined if Ep and/or milrinone were needed
over 48 hours to maintain normal hemodynamic param-
eters (normal HR, normal urine output, normal MAP,
normal capillary refill time, warm extremities) without
metabolic acidosis (standard plasma bicarbonate (HCO3
–)
level less than 22 mmol⋅L-1 or an increase in plasma lac-
tate level greater than 2.2 mmol⋅L-1) [2,11]. In this study,
no other catecholamines or corticosteroid was used in the
first 6 hours following open heart surgery.
Blood sampling
An initial blood sample (C0) was collected prior to CPB
after which Ep infusion was initiated. A second blood
sample (C1) was drawn at least 60 minutes after initiat-
ing Ep infusion. A last blood sample (C2) was drawn
40 minutes after a change in rate flow or prior to 6 hours
after beginning Ep infusion in the case of a constant flow
rate.
The 60-minute steady-state interval was chosen ac-
cording to at least five times the Ep plasma half-life in
healthy subjects (approximately 20 minutes) and the
dead volume of the CVC used to infuse Ep at 0.3 to
1 mL⋅h-1 rate flow (approximately 40 minutes) [4].
C0 was used to assess plasma levels of endogenous Ep.
Only C0 and C1 were drawn in patients who weighed less
than 2,500 g, according to the percentage of blood volume
permitted by the Ethics Committee of our institution.
Sample handling
Blood assigned to catecholamine assays was sampled in
EDTA-tubes placed in an ice bucket then immediately
centrifuged at 3,000 g for 5 minutes. The plasma samples
were then separated and immediately stored at −20°C and
thereafter at −80°C before 24 hours running.
Assay
Ep concentrations were blindly determined by means of
HPLC with colorimetric detection [12]. After thawing,
the volume of each sample was adjusted to 4 mL by
adding distilled water and the internal standard, dihy-
droxybenzylamine. A 20-μL aliquot at 10°C was then
injected into the chromatographic system comprised of
a column (25 cm × 4.6 mm inner diameter, 5 μm
Supelcosil LC-18 SupelcoTM), an electrochemical ESA
colorimetric detector (Model Coulochem III, EurosepTM),
dual analytic cells (ESA cell Model 5011) set at −0.05 V
for the first detector and −0.3 V for the second detector,
and a conditioning cell set at +0.3 V. The mobile phase, at
1.2 mL⋅min-1, consisted of a mixture of an aqueous acidic
buffer containing heptane sulfonic acid and acetonitrile
(93:7 v/v). Ep calibration curves were prepared according
to the same procedure (2.5 μg to 75 μg/4 mL distilled
water). The measured Ep concentration in pmol⋅mL-1 was
converted to μg⋅L-1. The detection threshold (defined
by variability <10% between measurements) for HPLC was
0.2 pmol⋅mL-1. Endogenous and exogenous Ep were
strictly identical with regard to chromatographic detection.
Patient data
Baseline patient characteristics were recorded, including
non-cardiac medical history, gender, age, BW, RACHS-1
category, type of congenital heart defect, preoperative
cyanotic status and left ventricular ejection fraction, dur-
ation of CBP and aortic cross-clamping, duration of
pCVICU stay, mechanical endotracheal ventilation dur-
ation and death during pCVICU stay. Duration of both
Ep and milrinone infusion were recorded. Variation of
infused doses was recorded during the first 6 hours.
HR (beats⋅min-1) and invasive MAP (mmHg) data were
recorded prior to CPB, at initiation of Ep, and then every
10 minutes for the first hour and thereafter every hour or
less if needed during the subsequent 6 hours. Left ven-
tricular ejection fraction (%) was measured at least once
during the 6 hours. CVP (mmHg) was systematically
recorded as well as LAP (mmHg) when measured.
Temperature (°C) and urine outputs (mL⋅kg-1⋅h-1) were
recorded during 6 hours following CBP.
Plasma lactate and glucose levels (mmol⋅L-1) were re-
corded before surgery and at least once thereafter during
the following 6 hours. Arterial pH, ionized plasma calcium
levels (mmol⋅L-1) and plasma HCO3
– levels (mmol⋅L-1)
were recorded during the first 6 hours.
Results are expressed as raw numbers (%) or medians
(ranges). The non-parametric Wilcoxon test was per-
formed to compare pharmacokinetic and pharmacody-
namic values before and under Ep infusion. P <0.05 was
considered statistically significant.
Pharmacokinetic-pharmacodynamic modeling
Ep concentration time-courses were described by a one-
compartment open model with first-order elimination
with the parameters of elimination clearance (CL) and
volume of distribution (V). The differential equation
connected to this model is thus,
dA tð Þ=dt ¼ Rate – CL:C tð Þ ð1Þ
with C tð Þ ¼ A tð Þ=V ð2Þ
where A(t) and C(t) denote the amount of drug and con-
centration of drug in the body at time t. The endogenous
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production rate, q0, was taken into account in the model
as follows,
C tð Þ ¼ A tð Þ=V þ q0=CL ð3Þ
The effect of BW was investigated in the pharmacoki-
netic model via an allometric relationship [13].
P ¼ PTYP BWð Þ
PWR ð4Þ
where P, PTYP and PWR are the individual parameter,
typical parameter and power exponent, respectively. The
PWR exponent was estimated in a first attempt and then
eventually fixed to ¾ for CL and q0 terms according to
the typical weight-based allometric rule.
The circulating volume, VCirc (L), was related to BW
as follows [14].
VCirc ¼ 0:08:BW ð5Þ
As kinetics data were best described by a one-compartment
model with first-order elimination, the half-life (T½)
was related to V and CL as T½ = ln2 .V/CL = 0.69.V/CL.
The HR response, HR(t), was related to the Ep con-
centration via an Emax model.
HR tð Þ ¼ HR0 þ HRmax−HR0ð Þ:C tð Þ= C tð Þ þ C50HRf g
ð6Þ
where HRmax and HR0 are respectively the maximal and
basal HR values and C50HR the concentration that in-
duces 50% of the maximal effect on HR.
The MAP(t) is then expressed as:
MAP tð Þ ¼ HR tð Þ:SV:SVR tð Þ þ CVP ð7Þ
where SV, SVR and CVP represent stroke volume, sys-
temic vascular resistance and central venous pressure, re-
spectively [15]. As SV and SVR were not known, the SV.
SVR product variation was estimated via the function.
SV:SVR tð Þ ¼ SV:SVR0 þ SV:SVRmax−SV:SVR0ð Þ:C tð Þ=
C tð Þ þ C50SV:SVRf g
ð8Þ
where SV⋅SVR0, SV⋅SVRmax and C50SV⋅SVR respectively
denote the SV⋅SVR product basal value, the product’s
maximal value and the concentration that induces 50%
of the maximal effect on SV⋅SVR.
Plasma glucose and lactate, G(t) and L(t), variations
were modeled by a turnover model in which the stimula-
tion of plasma glucose production, S(t), was related to
Ep concentration as follows.
dG tð Þ=dt ¼ RGLY:S tð Þ–kGLY:G tð Þ ð9Þ
with
S tð Þ ¼ 1þ GmaxC tð Þ= C tð Þ þ C50GLYf g ð10Þ
where RGLY and kGLY represent the plasma glucose zero-
order rate production and first-order elimination rate
constant. Gmax and C50GLY denote respectively the
maximal stimulation effect and the Ep concentration
that produces 50% of the maximal response.
The rate of change in plasma lactate level, dL(t)/dt,
was related to the plasma glucose level variation rate as:
dL tð Þ=dt ¼ kGLY:G tð Þ–kLAC:L tð Þ ð11Þ
where kLAC is the plasma lactate elimination rate constant.
Before Ep infusion, the systems are assumed to be at
steady-state,
G(0) = GLY0, L(0) = LAC0, then kGLY and kLAC are
kGLY ¼ RGLY=GLY0 ð12Þ
kLAC ¼ kGLY:GLY0=LAC0 ð13Þ
where GLY0 and LAC0 denote respectively, basal plasma
glucose and lactate levels.
Population pharmacokinetic-pharmacodynamic analysis
Drug concentrations and responses were analyzed using a
population approach, that is, a non-linear mixed-effect mod-
eling approach. Data were analyzed using the MONOLIX
software version 4.13 s [16] and the SAEM algorithm [17].
Differential equations were written in an MLXTRAN script
file in MONOLIX to estimate the parameters. Residual
variabilities were described by additive, proportional or ex-
ponential error models depending on the observation. An
exponential model was used for between-subject variability
(BSV). The effect of a covariate on a structural parameter
was retained if it caused a decrease in the Bayesian informa-
tion criterion (BIC) and/or reduced the corresponding BSV
with P <0.05. Only covariates with a plausible effect on phar-
macokinetic and pharmacodynamic parameters were inves-
tigated. The main covariates of interest in this pediatric
population were BW and age.
Visual predictive check (VPC) evaluation
Plasma Ep concentration, HR, MAP, plasma glucose and
lactate-level time course was simulated from the respect-
ive final population model and compared with the ob-
served data to evaluate the predictive performance of
the model. The vector of pharmacokinetic parameters
from 400 replicates of the database was simulated using
the final model. Each vector parameter was drawn in a
log-normal distribution with a variance corresponding to
the previously estimated BSV. A simulated residual error
was added to each simulated concentration. The 5th, 50th
and 95th percentiles of the simulated dependent variables
at each time point were then overlaid on the observed
data and a visual inspection was performed. Because the
patients received different Ep regimens, the Uppsala
correction was used to produce the VPC plots [18].
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Evaluation and validation
Diagnostic graphics were used for evaluation of the
goodness-of-fit. Concentration and effects profiles were
simulated and compared with the observed data with
the aid of the VPC in order to validate the model.
Results
Patients
A total of 55 children were initially enrolled, of which 16
patients were subsequently excluded: 6 because of incom-
plete parental consent, 7 because of missing C1 and C2
blood samples and 2 because of hemolysis.
Hence, 39 children were included in the study. C0 sam-
ples were obtained in 33 patients, C1 in all children and C2
in 25 children for a total of 97 observations. Hemodynamic
data (HR, MAP) and metabolic effects of Ep infusion
(plasma lactate and glucose levels) were available in 38 chil-
dren with 434, 464, 101 and 140 observations, respectively.
Five premature children with a gestational age <37 weeks
(n = 1 at 33 weeks, n = 1 at 34 weeks, and n = 3 at 36 weeks)
were recorded. Chromosomal disorders were reported in
eight children (n = 3 with Down syndrome, n = 1 with
di George syndrome, n = 1 with Loeys-Dietz syndrome,
and n = 1 with Noonan syndrome n = 2 with suspected
Noonan syndrome). Respiratory disorders were noted
in seven patients (n = 3 with asthma, n = 3 with laryn-
gotracheomalacia, and n = 1 with chronic aspiration
pneumonia) and malnutrition (<2 SD) was observed in
nineteen children.
Six children were treated before open heart surgery
with converting enzyme inhibitors because of left ven-
tricular dilatation, seven were treated with prostaglan-
dins because of ductus arteriosus-dependent heart disease,
and β-blockers were co-administered to three children be-
cause of obstruction of the left ventricular outflow track.
All children had transthoracic echocardiography prior
to CPB; left ventricular ejection fraction was evaluated at
60% (25 to 78) with normal values (>50%) observed in
34 patients (87%). Ventricular diastolic function was not
assessed. Eleven children were cyanotic (SpO2 <90%) prior
to the surgery because of their congenital heart disease.
Open heart surgeries were as follows: arterial switch (n = 9),
repair of complete atrioventricular canal (n = 6), repair of
ventricular septal defect (n = 6), total repair of tetralogy of
Fallot (n = 4), pulmonary valvuloplasty (n = 3), repair of co-
arctation and ventricular septal defect closure (n = 2), repair
of interrupted aortic arch with ventricular septal defect
closure (n = 2), repair of double-outlet right ventricle
(n = 2), repair of pulmonary artery stenosis (n = 2), pul-
monary valvular replacement (n = 2), and repair of truncus
arteriosus (n = 1). Surgery with deep hypothermic circula-
tory arrest was necessary in 11 children.
In the operating room all children required the follow-
ing: a red blood cell transfusion, fresh-frozen plasma
administration, neuromuscular blocking agents, and
hypnotic and opioid drug infusion. Ultrafiltration of
650 mL (250 to 1,200) of fluid during CPB was per-
formed to achieve a negative fluid balance and hematocrit
at 44% (35 to 47). Milrinone and Ep were initiated just be-
fore weaning from CPB, with an infused Ep dose of
0.07 μg⋅kg-1⋅min-1 (0.01 to 0.23) and an infusion milrinone
dose of 0.5 μg⋅kg-1⋅min-1 (0.2 to 0.7). Milrinone infusion
was stopped after 1.5 days (1 to 13).
Delayed sternal closure occurred in four patients. Post-
operative left ventricular ejection fraction under Ep and
milrinone infusion was at 60% (30 to 70) with normal
values (>50%) observed in 34 patients (87%). CVP and
LAP were 11 mmHg (8 to 15) and 8 mmHg (6 to 14),
respectively. Four children exhibited supraventricular
tachycardia, one had ventricular tachycardia and five had
a transient atrioventricular block, which required exter-
nal cardiac pacing. Urine output was 4.5 mL⋅kg ⋅h-1 (0.8
to 7.5) and pH, plasma HCO3
– (mmol⋅L-1) and plasma
ionized calcium (mmol⋅L-1) levels were: 7.39 (7.27 to
7.45); 24 (20 to 26) and 1.28 (1.12 to 1.5), respectively.
All children required diuretics, whereas none were under
corticosteroid therapy during the 6 hours following sur-
gery. Ten children needed inhaled nitric oxide for pulmon-
ary arterial hypertension during the postoperative course.
Endotracheal mechanical ventilation was performed for all
patients during 2.1 days (1 to 17). None of the patients re-
quired renal replacement therapy and none had liver injury
according to prothrombin activity and/or Factor V levels
(lower than 50% for at least 24 hours). None of the chil-
dren died during their pCVICU stay. Finally, nine children
(23%) had LCOS according to the classical definition.
Table 1 summarizes overall patient characteristics.
Epinephrine pharmacokinetics
The increase in Ep concentration during infusion was sig-
nificant: 2.94 μg⋅L-1 (0.37 to 71) compared to baseline Ep
concentration, 0.062 μg⋅L-1 (0.037 to 0.25) (P <0.001). A
one-compartment open model with linear elimination ad-
equately described the Ep time courses. An additional
movie file shows this in more detail (see Additional file 1).
The pharmacokinetic parameters were V, CL and q0. The
residual variability was ascribed to a proportional
model. BW was the main covariate influencing CL and
q0 (P <0.001). Both PWR estimates for q0 and CL were
close to 1 (0.98 and 0.985), however CL and q0 were
poorly estimated (relative standard errors near 50%).
Moreover, BIC decreased from 214.2 to 205.0 when
PWR was estimated and further decreased to 199.0
when PWR was fixed to ¾. Also, there was no visible
or significant difference between the two models on
the observed versus predicted plots. An additional
movie file shows this in more detail (see Additional
files 2 and 3).
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Hence, these power values were fixed to ¾ according
to the BW-based allometric rule. V was assumed to be
equal to the circulating volume because V could not be
accurately estimated and because of the hydrophilic na-
ture of Ep. No other covariate (gender, pH, temperature,
RACHS-1 categories, creatinine clearance, gestational
age, cyanosis, malnutrition) influenced the pharmacokin-
etics. The final relationship for Ep CL and q0 was:
CL(BWi) = θCL × (BWi)
3/4 and q0(BWi) = θq0 × (BWi )
3/4,
then
θCL (L⋅h
-1
⋅kg-1) = 2, θq0 (μg⋅h
-1
⋅kg-1) = 0.15
where θCL and θq0 are typical unit clearance and en-
dogenous production rate. For an individual weighing
10 kg, Ep CL, q0, V and T½ were:
CL (10 kg) = 2 × 10¾ = 11.2 L⋅h-1, q0 (10 kg) = 0.15 ×
10¾ = 0.84 μg⋅h-1, V(10 kg) = 0.08 × 10 = 0.8 L and
T½(10 kg) = (ln2 × V(10 kg) /CL(10 kg)) × 60 = 3 minutes.
Table 2 summarizes the final population estimates. All
parameters were estimated with good precision. Figure 1
depicts the VPC and shows that the observed concentra-
tions were well centered around the simulated median
predictions.
Epinephrine hemodynamics
After initiation of Ep infusion, (i) HR increased significantly
from 135 beats⋅min-1 (70 to 180) to 159 beats⋅min-1 (80 to
212) (variance (w) = 2563; P = 2.10-8), (ii) MAP values
increased significantly from 51 mmHg (25 to 65) to
Table 1 Patient characteristics and baseline kinetic and
dynamic data
Patient characteristics (n = 39) Values
Demographics
Age, months 3.9 (0.1 to 189)
Gender, male, n (%) 26 (66.6%)
Body weight, kg 4.5 (2.5 to 58)
Preoperative physiological profile
RACHS-1, categories, median (range) 3 (2 to 4)
Category 2, n 16
Category 3, n 17
Category 4, n 6
Prothrombin activity (%) 80 (50 to 100)
Creatinine clearance, mL⋅min-1⋅1.73 m(2) -1 91 (22 to 200)
Per-operative course
Duration of CPB, minutes 107 (52 to 222)
Aortic cross-clamping time, minutes 64 (9 to 140)
Postoperative course
Ep infusion duration, days 1.5 (1 to 13)
pCVICU length of stay, days 3 (2 to 23)
Baseline kinetic and dynamic parameters
Ep concentration, μg⋅L-1 0.062 (0.037 to 0.25)
Heart rate, beats⋅min-1 135 (70 to 180)
Mean arterial pressure, mmHg 51 (25 to 65)
Plasma glucose level, mmol⋅L-1 6.2 (4 to 10.1)
Plasma lactate level, mmol⋅L-1 1 (0.5 to 3)
RACHS, risk adjustment for congenital heart surgery; n, number; CPB,
cardiopulmonary bypass; min, minutes; Ep, epinephrine; pCVICU, pediatric
cardiovascular intensive care unit. Values represent median and the
presentation of the value in parentheses defined the range from (min to max).
Table 2 Population pharmacokinetic parameters
Parameters Estimate RSE (%)
θCL (L⋅h
-1
⋅kg-1) 2 17
θBW (CL(BWi) = θCL × BWi
3/4 ) 0.75 (fixed) NA
θq0 (μg⋅h
-1
⋅kg-1) 0.15 19
θBW (q0(BWi) = θq0 × BWi
3/4 ) 0.75 (fixed) NA
V (L) for a 10 Kg individual 0.8 NA
T½ (min), for a 10 Kg individual 3 NA
ηCL (square root of ω
2
CL) 1 14
ηq0 (square root of ω
2
q0) 1.1 13
Residual variability (proportional) 0.3 15
Correlation (ηCL, ηq0) 0.88 5
The volume of distribution of epinephrine was ascribed to the circulating
volume, estimated as a function of bodyweight (see Materials and methods).
CL, elimination clearance; q0, endogenous production rate; V, volume of
distribution; CV, circulating volume; θCL, typical unit clearance; θq0,typical unit
endogenous production rate; θBW, bodyweight influential parameter; T½, half-life.
RSE, relative standard error; η, between-subject variability (BSV); BW, bodyweight;
NA, not applicable.
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Figure 1 Prediction corrected-visual predictive check (PC-VPC)
for epinephrine concentrations versus time in minutes. The
green lines depict the 5th, 50th and 95th percentiles of observed
data; the areas represent the 95% confidence interval around the
simulated percentiles. Blue color represent the 5th and the 95th
percentile of the predicted concentration versus time and pink color
represent the median predicted concentration versus time. Time
0 min represents the starting time of epinephrine infusion.
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66 mmHg (30 to 94) (variance (w) = 2613; P = 5.10-11)
(Figure 2). The variations in HR and MAP as a func-
tion of Ep concentration were well explained by the
Emax models, expressed by equations (6) to (8). The
residual variability was ascribed to a proportional model.
BSVs were estimated for HR0, C50HR, SV.SVR0 and SV.
SVRmax. Age was the main covariate influencing HR0 and
SV⋅SVR0 (P <0.001) where HR0i =HR0 × agei
-0.0612 and
SV.SVR0i = SV⋅SVR0 × agei
0.094 respectively. Including age
in the model dramatically decreased the BIC (from 5,998
to 5,971) and improved the curve-fitting of the model. In
addition, RACHS-1 category was significant (P = 0.04) in
the estimation of SV⋅SVRmax: 0.44 and 0.26 for RACHS-1
categories 2 and 3 to 4 respectively; the BSVs for HR0,
C50HR, SV⋅SVR0 and SV⋅SVRmax varied from 0.19, 1.0,
0.25 and 0.32 (basic model) to 0.14, 1.22, 0.13 and 0.23
(final model). Also, the BIC decreased from 5,971 (includ-
ing age) to 5,965 (final model).
No other covariate improved the model (including dur-
ation of aortic cross-clamping, duration of CPB, deep
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Figure 2 Box and whisker plots of hemodynamic and metabolic data before and during epinephrine infusion. Box and whisker plots of
(i) heart rate, beats⋅min-1 (A) before epinephrine infusion (minimum= 70; maximum (max) = 180; median = 135) and during epinephrine infusion
(minimum= 70; max = 212; median = 159) (variance (w) = 2,563; P = 2.10-8); (ii) mean arterial pressure, mmHg (B) before epinephrine infusion
(minimum= 25; max = 65; median = 51) and during epinephrine infusion (minimum= 30; max = 94; median = 66) (variance (w) =2613; P = 5.10-11);
(iii) plasma glucose, mmol⋅L-1 (C) before epinephrine infusion (minimum = 4; max = 10.1; median = 6.2) and during epinephrine infusion
(minimum = 4.9; max = 23.3; median = 9.85) (variance (w) = 339; P = 6.10-9) and (iv) lactate levels, mmol⋅L-1 (D) before epinephrine infusion
(minimum= 0.5; max = 3; median = 1) and during epinephrine infusion (minimum= 0.9; max = 7.1; median = 2.1) (variance (w) = 218; P = 3.10-10).
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hypothermia and milrinone dosage). The final population
parameters are summarized in Table 3. The VPC plots in
Figure 3 show that the observed HR and MAP values are
well-centered around the predicted median of the model.
Metabolic effects of epinephrine
Both plasma glucose and lactate levels increased signifi-
cantly after the initiation of Ep infusion from 6.2 mmol⋅L-1
(4.0 to 10.1) and 1 mmol.L-1(0.5 to 3) to 9.85 mmol.L-1 (4.9
to 23.3) [variance (w) = 339; P = 6.10-9] and 2.1 mmol⋅L-1
(0.9 to 7.1) (variance (w) = 218; P = 3.10-10), respectively
(Figure 2). Assuming that Ep stimulated the glucose pro-
duction rate, the turnover models expressed by equations
(9) to (13) effectively described the variations in plasma
glucose (G(t)) and lactate levels (L(t)). There was no signifi-
cant covariate effect, including those of exogenous glucose
supply, age or BW. The residual variability was ascribed to
a constant additive model. BSVs were estimated for GLY0,
RGLY, Gmax and LAC0. All parameters were well-estimated
with low relative standard errors. Table 3 summarizes the
population estimates. The VPC plots in Figure 4 show that
the observed plasma glucose and lactate levels are well-
centered around the predicted median of the model.
Epinephrine dosing simulations
Using the hemodynamic model, the effects of various infu-
sion rates of Ep on HR and MAP were assessed as a func-
tion of age and BW. As shown in Figure 5, the increase in
Ep concentration versus infusion rate was linear although
the increases in HR and MAP were curvilinear, due to
the Ep concentration-Emax model. Similarly, Figure 6
shows the metabolic responses for a child weighing 5 kg
with three infusion rates: 0.02, 0.1 and 0.25 μg⋅kg⋅min-1.
Discussion
Little is known about the pharmacokinetics and pharma-
codynamics of Ep in children although this drug is used
in the pediatric population. The present study using a
population approach adequately described the kinetics,
hemodynamic and metabolic effects of Ep in critically ill
children, highlighting the between-subject variabilities
which were well explained by age and BW.
Epinephrine pharmacokinetics
A one-compartment open model with linear elimination
adequately described the data as previously reported
[3,5,19]. The effect of BW using the allometric scale on
clearance and Ep endogenous production improved the
model and partly explained the between-subject variabil-
ity [13]. This was not unexpected since endogenous rates
of production and clearance of Ep are dependent on en-
zymatic maturation, both of which are related to age and
BW [20]. With regard to endogenous Ep rate produc-
tion, given that the concentrations observed following
the infusion were well above 10-fold the baseline con-
centrations (approximately 50-fold), the contribution of
possible variations in endogenous production was as-
sumed to be negligible during the infusion. We could
not adequately estimate volume of distribution because
Ep concentration was measured only in the steady state;
however, adjusting the volume of distribution to the
circulating volume is justified considering the hydro-
philic nature of Ep. We did not find any effect of
Table 3 Hemodynamic and metabolic population
parameters
Hemodynamic population parameters Estimate RSE (%)
HR0 (b⋅min
-1) 133 3
θage (HR0i = HR0 x agei
-0.061) −0.061 18
HRmax (b⋅min
-1) 180 3
C50 HR (μg⋅L
-1) 5.71 37
SV⋅SVR0 0.31 3
θage (SV⋅SVR0i = SV⋅SVR0 x agei
0.094 ) 0.094 14
SV⋅SVRmax, RACHS-1 = category 2 0.44 20
SV.SVRmax, RACHS-1 = categories 3,4 0.26 20
C50 SV⋅SVR (μg.L
-1) 18 59
ηHR0 (square root of ω
2
HR 0) 0.14 14
ηC50 HR (square root of ω
2
C 50 HR) 1.22 17
ηSV.SVR0 (square root of ω
2
SV.SVR0) 0.13 17
ηSV.SVRmax (square root of ω
2
SV.SVRmax) 0.23 42
Residual variability (proportional)
HR 0.08 4
MAP 0.16 4
Metabolic population parameters
GLY0 (mmol⋅L
-1) 5.46 5
Gmax 1.69 6
RGLY (mmol⋅L
-1.min-1) 0.04 25
C50GLY (μg⋅L
-1) 0.52 9
LAC0 (mmol⋅L
-1) 1.23 7
ηGLY0 (square root of ω
2
GLY 0) 0.21 23
ηGmax (square root of ω
2
Gmax) 0.213 26
ηRGly (square root of ω
2
RGLY) 1 21
ηLAC0 (square root of ω
2
LAC0) 0.33 18
Residual variability (constant additive)
GLY (mmol⋅L-1) 2.23 5
LAC (mmol⋅L-1) 0.5 11
HR0, basal heart rate; HRmax, maximal HR; C50HR, Ep concentration producing
50% of HR max; SV⋅SVR, product of stoke volume by systemic vascular
resistances; SV⋅SVR0, basal SV⋅SVR value; SV.SVRmax, maximal SV⋅SVR value;
C50SV⋅SVR, Ep concentration producing 50% of SV⋅SVRmax; RACHS-1, risk ad-
justment for congenital heart surgery 1; GLY0, basal plasma glucose level;
RGLY, glucose zero-order production rate; Gmax, relative maximal increase in
RGLY; C50GLY, Ep concentration that produces 50% of the maximal response
on plasma glucose level; LAC0, basal plasma lactate level; RSE, relative standard
error; η, between-subject variability (BSV); θage, age influential parameter.
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creatinine clearance, as only 10% of Ep is excreted
unchanged via the renal route and is mainly and rapidly
inactivated by either methylation via the effect of
catechol-O-methyl transferase or oxidative deamination
by monoamine oxidase into inactive metabolites excreted
by the kidney [21]. In contrast to the study of Abboud
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Figure 3 Prediction corrected-visual predictive check (PC-VPC) for heart rate (A) and mean arterial pressure (B) observations versus
time in minutes. The green lines depict the 5th, 50th and 95th percentiles of observed data; the areas represent the 95% confidence interval
around the simulated percentiles. Blue color represent the 5th and the 95th percentile of the predicted HR and MAP versus time and pink color
represent the median predicted HR and MAP versus time. Time 0 min represents the starting time of epinephrine infusion.
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et al., neither RACHS-1 categories nor duration of CBP
or aortic cross-clamping, which reflect the severity of
illness, were found to be significant, possibly because of
the small sample size and the difference in patient age
and illness groups between the studies [6].
Epinephrine - hemodynamic effects
To the best of our knowledge, this is the first study in
which the hemodynamic responses to Ep in preventing
LCOS were modeled. Only HR and MAP were recorded
in this study. In adult volunteers, as in critically ill
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Figure 4 Prediction corrected-visual predictive check (PC-VPC) for plasma glucose level (A) and plasma lactate level (B) observations
versus time in minutes. The green lines depict the 5th, 50th and 95th percentiles of observed data; the areas represent the 95% confidence interval
around the simulated percentiles. Blue color represent the 5th and the 95th percentile of the predicted plasma glucose level and lactate level versus time and
pink color represent themedian predicted plasma glucose level and lactate level versus time. Time 0min represents the starting time of epinephrine infusion.
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patients, Ep increases HR as well as MAP [8,22,23]. The
predominant effect of Ep when administered at low dose
is mediated by β-adrenergic receptors, which increase
HR and SV [23-25]. The resulting hemodynamic re-
sponse may differ in children because of (i) the relative
immaturity of the myocardium, which precludes a sig-
nificant increase in SV [26] and (ii) a variation in β1 and
β2-adrenergic receptor density related to age [27]. Fur-
thermore, newborn and infant cardiac outputs are more
dependent on an increase in HR [25]. This is confirmed
by our hemodynamic model, which highlighted the pri-
mary role of HR, which in turn influences MAP, that is,
the C50 estimate for the SV⋅SVR product was three
times as high as that estimated for HR, reflecting a
much greater sensibility of the HR response to Ep.
The Emax models were effective in relating both HR
and MAP responses to Ep concentration [28]. Measuring
cardiac output is hazardous in children undergoing re-
pair of congenital heart disease because of residual ven-
tricular and/or auricular shunt. Hence, we could only
estimate the SV⋅SVR product that relates MAP to HR.
Moreover, as expected, age was found to be a significant
covariate that dramatically improved the model: HR was
negatively related to age whereas the SV⋅SVR product
increased with age. This latter finding is easy to explain
because both SV and MAP increase with age [29]. Like-
wise, RACHS-1 categories 3 and 4 decreased the max-
imal MAP response (SV⋅SVRmax product). This effect
may be related to the role of systemic inflammatory syn-
drome following CB, which alters myocardial and vascu-
lar response to Ep [11]. The impact of temperature and
pH on HR was also investigated but was not found
significant.
As milrinone was infused in all children, this could
have had a confounding effect on hemodynamic re-
sponses. There are conflicting data in the literature on
the effect of milrinone on HR, namely an increased or
unchanged HR [30]. In the present study, none of the
parameters of the hemodynamic model were found to be
influenced by a dose-dependent effect of milrinone.
Moreover, any possible confounding effect would be neg-
ligible since an immediate increase in HR was observed
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after Ep initiation which is not compatible with the de-
layed response to milrinone [31].
Epinephrine - metabolic effects
The turnover model herein provided a valid relationship
between Ep concentration and plasma glucose and lac-
tate levels, as these metabolic responses are dependent
on stimulation of glycogenolysis via the activation of
β2-adrenergic receptors [32]. During Ep infusion, the in-
creases in plasma glucose and lactate levels were signifi-
cant, albeit delayed as compared to the hemodynamic
responses. Indeed, exogenous Ep has previously been
shown to increase plasma glucose and lactate levels
[8,33]. Lactate is mainly produced via the anaerobic
glycolytic breakdown of glucose to pyruvate [32]. An ex-
cessive vasoconstriction mediated by α-adrenergic recep-
tors results in lactate accumulation due to limited
oxygen supply [34]. However, lactate may also accumu-
late during accelerated aerobic glycolysis driven by Ep
[35], and it is unlikely that the rise in plasma lactate
level is due to an excessive vasoconstrictor effect via
Ep α-adrenergic receptor stimulation, given the low
doses administered. Lastly, we believe that these in-
creases are strongly related to Ep without confounding
factors because (i) there was no significant effect of the
exogenous supply of glucose, (ii) there were no other
potential hyperglycemic treatments, such as corticoste-
roids and (iii) milrinone does not elevate glucose and/
or lactate levels [36].
Epinephrine dosing simulations
Using the final model, it was possible to highlight the
differences in responses to a same infusion rate accord-
ing to age or BW. Therefore, these simulations allow the
determination of an a priori dosing schedule, for specific
BW and age, to produce a suitable increase in HR and
MAP. Interestingly, these plots clearly show that the
amplitude of HR or MAP increase following various Ep
infusion rates is related to the child’s BW, that is, the
lower the BW, the smaller the amplitude of increase.
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Limitations of the study
The small sample size likely limited the identification of
other significant covariates that could affect either the
pharmacokinetics or the responses to Ep. We were not
able to evidence a hemodynamic effect of milrinone in
the model; however, we cannot ignore the potential ef-
fect of the latter and must assume that the modeling of
the hemodynamic effects of Ep, including its simula-
tions, implicitly take into account the effects of milri-
none. Furthermore, such simulations need to be confirmed
in a future clinical study. Finally, as only children who
underwent an open heart surgery with CPB were included,
our results cannot be easily extended to patients with other
circulatory failure etiologies.
Conclusion
This original study on pharmacokinetics, hemodynamic
and metabolic effects of Ep to prevent postoperative
LCOS in children highlights as expected, clear between-
subject variability related to the substantial role of age
and BW. Taking into account these individual character-
istics should help clinicians in determining an appropri-
ate a priori dosing regimen.
Key messages
 In critically ill cardiac postoperative children, lower
bodyweight was associated with lower epinephrine
clearance.
 Differences of hemodynamic responses to
epinephrine were related to age and bodyweight: the
lower the bodyweight, the smaller the amplitude of
heart rate and mean arterial pressure increase.
 Increase of plasma glucose and lactate levels was
related to epinephrine concentration without any
effect of age, bodyweight or exogenous glucose
supply.
 Epinephrine dosing simulations should help the
clinician in determining an appropriate a priori
dosing regimen.
Additional files
Additional file 1: Example of epinephrine concentration time
courses in 16 individual fits. We can see the satisfactory adequacy
between predicted (green curve) and observed (blue cross) epinephrine
concentration (μg⋅L-1) time (min) courses.
Additional file 2: Population pharmacokinetics of epinephrine:
estimation of the power coefficients for the bodyweight effect.
Additional file 3: Predicted versus observed plots for the fixed and
estimated allometric power coefficients. We can observe that there is
no visible or significant difference between the two models.
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